Song Tao, Yu Wei, Wu Shi-Xiu
Department of Radiation Oncology, The First Clinical College of Wenzhou Medical University, Hangzhou Cancer Hospital, Hangzhou, China E-mail :
Asian Pac J Cancer Prev. 2014;15(1):205-13. doi: 10.7314/apjcp.2014.15.1.205.
The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great advantages over traditional treatment strategies in patients with non-small cell lung cancer (NSCLC), but unfortunately we have to face the situation that most patients still fail to respond in the long term despite initially good control. Up to now, the mechanism of acquired resistance to EGFR-TKIs has not been fully clarified. Herein, we sought to compile the available clinical reports in the hope to better understanding the subsequent treatment choices, particularly on whether restoring after a drug holiday or switching to another EGFR-TKI is the better option after failure of one kind of EGFR-TKI.
第一代表皮生长因子受体酪氨酸激酶抑制剂（吉非替尼和厄洛替尼）在非小细胞肺癌（NSCLC）患者中的治疗效果已显示出相对于传统治疗策略的巨大优势，但不幸的是，我们不得不面对这样的情况：尽管大多数患者最初控制良好，但从长期来看，仍有多数患者出现耐药。到目前为止，表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的机制尚未完全阐明。在此，我们试图汇总现有的临床报告，以期更好地了解后续的治疗选择，特别是在一种表皮生长因子受体酪氨酸激酶抑制剂治疗失败后，停药后恢复用药还是换用另一种表皮生长因子受体酪氨酸激酶抑制剂是更好的选择。
